I'm LongbridgeAI, I can summarize articles.Moderna shares rose nearly 3% in pre-market trading following positive Phase 3 trial results for its personalized mRNA cancer vaccine, intismeran autogene, which met its primary endpoint in treating melanoma. This milestone marks the first positive late-stage readout for an mRNA cancer vaccine. The rally was further fueled by upgraded analyst price targets from Barclays and Wolfe Research, alongside broader market gains. The partnership with Merck highlights significant commercial potential, with peak sales projected near $9.2 billion.
Moderna snapped up nearly 3% in pre-market trading, shaking off some recent profit-taking after its eye-popping surge earlier this year. The biotech's star shot rose after news broke that its personalized mRNA cancer vaccine, intismeran autogene, hit its primary endpoint in a pivotal Phase 3 trial targeting melanoma.
This marks a milestone: it's the first positive late-stage readout for an mRNA cancer vaccine, showing a significant drop in melanoma recurrence among patients who had their tumors removed surgically. The study was a joint effort with partner Merck.
Investors digested this breakthrough differently over the past days, with early enthusiasm followed by some pullback and skepticism about how well the treatment will perform commercially. The mixed reactions climbed higher today, fueled by Barclays analyst Eliana Merle upping her price target on Moderna shares sharply from $48 to $125, while keeping her Equal Weight rating. This follows a prior upgrade from Wolfe Research, nudging the rating from Underperform to Peer Perform and projecting peak sales nearing $9.2 billion across four cancer indications before splitting profits with Merck.
The macro picture lends a bit of a tailwind too, with major U.S. indexes nudging up. The Nasdaq is up about 1%, and the S&P 500 is showing modest gains, creating a friendlier backdrop for higher beta names like biotech stocks.
It's been a wild ride for Moderna this year, having surged close to 400% following the initial Phase 3 success, before settling back amid broader sector rotation and questions about market appetite for emerging therapies. Meanwhile, Merck has also benefited from the encouraging data, highlighting the potential commercial synergy of the partnership.
Technically, after the recent pullback, Moderna's charts suggest some stabilization, which combined with the fresh analyst enthusiasm and the supportive broader market mood, helped shares tick higher this morning.
Looking ahead, the timeline for the product launch is possibly set around 2027, pending further data releases to support regulatory submissions and commercialization plans. For now, the market seems to be balancing excitement about the novel mRNA cancer vaccine approach with the usual caution that comes with new therapies in a competitive field.
Moderna's journey remains a fascinating case study in biotech volatility-rising on leaps forward and pausing for breath as investors reassess risks and rewards. Whether this rally gathers steam or stalls out depends on how subsequent trial data and market factors play out.